Sign in or Register   Sign in or Register
  |  

Mouse Anti-ALPL Recombinant Antibody (3A7) (CBMAB-A0315-LY)

The product is antibody recognizes ALPL. The antibody 3A7 immunoassay techniques such as: WB, ELISA.
See all ALPL antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
3A7
Antibody Isotype
IgG2b, κ
Application
WB, ELISA

Basic Information

Immunogen
ALPL (AAH21289, 28 a.a. ~ 137 a.a) partial recombinant protein with GST tag.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.4
Preservative
None
Concentration
Batch dependent
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Alkaline Phosphatase, Liver/Bone/Kidney
Introduction
There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The first three are located together on chromosome 2, while the tissue non-specific form is located on chromosome 1. The product of this gene is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. The exact physiological function of the alkaline phosphatases is not known. A proposed function of this form of the enzyme is matrix mineralization; however, mice that lack a functional form of this enzyme show normal skeletal development. This enzyme has been linked directly to hypophosphatasia, a disorder that is characterized by hypercalcemia and includes skeletal defects. The character of this disorder can vary, however, depending on the specific mutation since this determines age of onset and severity of symptoms. Alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq]
Entrez Gene ID
249
Alternative Names
AP-TNAP; FLJ40094; FLJ93059; HOPS; MGC161443; MGC167935; TNAP; TNSALP
Function
This isozyme plays a key role in skeletal mineralization by regulating levels of diphosphate (PPi).
Biological Process
Cellular response to organic cyclic compound Source: Ensembl
Cementum mineralization Source: Ensembl
Dephosphorylation Source: GO_Central
Developmental process involved in reproduction Source: Ensembl
Endochondral ossification Source: Ensembl
Osteoblast differentiation Source: UniProtKB
Response to antibiotic Source: Ensembl
Response to glucocorticoid Source: Ensembl
Response to lipopolysaccharide Source: Ensembl
Response to vitamin D Source: BHF-UCL
Skeletal system development Source: ProtInc
Cellular Location
Cell membrane
Involvement in disease
Hypophosphatasia (HOPS): A metabolic bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase. Four forms are distinguished, depending on the age of onset: perinatal, infantile, childhood and adult type. The perinatal form is the most severe and is almost always fatal. The adult form is mild and characterized by recurrent fractures, osteomalacia, rickets, and loss of teeth. Some cases are asymptomatic, while some patients manifest dental features without skeletal manifestations (odontohypophosphatasia).
Hypophosphatasia childhood type (HOPSC): A bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase.
Hypophosphatasia infantile type (HOPSI): A severe bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase. Three more or less distinct types of infantile hypophosphatasia can be identified: (1) type 1 with onset in utero or in early postnatal life, craniostenosis, severe skeletal abnormalities, hypercalcemia, and death in the first year or so of life; (2) type 2 with later, more gradual development of symptoms, moderately severe 'rachitic' skeletal changes and premature loss of teeth; (3) type 3 with no symptoms, the condition being determined on routine studies.
PTM
N-glycosylated.
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-ALPL Recombinant Antibody (3A7)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare